RT Journal Article SR Electronic T1 Tumor MHC-II Neoantigens Maintain CD8+ T-cell Antitumor Immunity JF Cancer Discovery JO Cancer Discov FD American Association for Cancer Research DO 10.1158/2159-8290.CD-RW2019-166 YR 2019 UL http://cancerdiscovery.aacrjournals.org/content/early/2019/11/01/2159-8290.CD-RW2019-166.abstract AB MHC class II restricted neoantigens play a critical role in response to immune checkpoint therapy (ICT).